Targeting cancer-associated fibroblasts through inhibition of protein synthesis to abrogate resistance to chemotherapies in pancreatic cancer
Camille Duluc(Inserm), Corinne Bousquet(Centre National de la Recherche Scientifique), Mounira Chalabi(Université Toulouse III - Paul Sabatier), Julie Guillermet‐Guibert(Centre National de la Recherche Scientifique), Barbara Garmy‐Susini(Inserm), Stéphane Pyronnet(Centre National de la Recherche Scientifique), Marie‐Bernadette Delisle(Inserm), Herbert Schmid(Novartis (Switzerland)), Siham Moatassim-Billah(Mohammed V University), Yvan Martineau(Centre National de la Recherche Scientifique), Florence Breibach(Pharmacochimie et Biologie pour le Développement)
Cited by 1
Related Papers
The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study
|The Lancet Neurology|2022|651
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
|British Journal of Pharmacology|2021|488
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390
Autoregulation of pituitary corticotroph SOCS-3 expression: Characterization of the murine SOCS-3 promoter
|Proceedings of the National Academy of Sciences|1999|290
Inter‐ and intra‐tumoural heterogeneity in cancer‐associated fibroblasts of human pancreatic ductal adenocarcinoma
|The Journal of Pathology|2018|284